Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen
JC Aguilar(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Dagmara Pichardo(Centro de Ingeniería Genética y Biotecnología), Verena Muzio(Centro de Ingeniería Genética y Biotecnología), Darién García(Centro de Ingeniería Genética y Biotecnología), David Silva(Canberra Hospital), Yadira Lobaina(Centro de Ingeniería Genética y Biotecnología), Eduardo Pentón(Centro de Ingeniería Genética y Biotecnología), Nikolai Petrovsky(Flinders Medical Centre), Enrique V. Iglesias(Sorbonne Université), Dioslaida Urquiza(Centro de Ingeniería Genética y Biotecnología)
Cited by 87
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134